An Open Label,Multi-center Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Autologous T Cell Injection Targeting GPRC5D OriCAR-017 in Patients With Relapsed and/or Refractory Multiplemyeloma
Latest Information Update: 05 Jun 2024
At a glance
- Drugs Ori CAR 017 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors OriCell Therapeutics
Most Recent Events
- 01 Jan 2024 New trial record